cellestia-biotech-employee

Dr. Marc Lang

Scientific Advisory Board Member

PhD in chemistry, has 30+ years of experience in medicinal chemistry in the pharmaceutical industry (Novartis). During his career, he contributed personally to three compounds currently on the market: Femara®(aromatase inhibitor); Reyataz® (HIV-protease inhibitor); Tasigna® (Bcr/Abl kinase inhibitor) and several promising compounds still in clinical trials. He now is scientific advisor to several pharmaceutical companies.
LinkedIn Profile